CML Pathology and the Quest for Effective Biomarkers
Posted: Tuesday, June 9, 2020
Chinese researchers identified three sets of biomarkers in the competitive endogenous RNA network in patients with chronic myeloid leukemia (CML), according to results published in BioMed Research International. Xu et al, of the Jiangnan University, China, suggest that further studies are warranted to identify additional biomarkers.
“The result will enhance our understanding of CML pathology from the competitive endogenous RNA perspective and help us discover the effective biomarkers of [chronic phase, accelerated phase, and blastic crisis] in CML, which help patients get timely treatment and thereby reduce the mortality rate,” the authors commented.
In this study, a total of three normal samples, six chronic phase patient samples, four accelerated phase patient samples, and two blastic phase patient samples of hematopoietic stem cells were the focus of attention. To gain the lncRNA expression profile data, a probe set was reannotated, resulting in a total of 848 probes, whereas for the mRNA expression profile, 181,288 mRNA expression profiles were obtained.
“By analyzing the functions of the identified competitive endogenous RNA network biomarkers, it has been found that they are effective lncRNA biomarkers directly or indirectly related to CML,” the investigators concluded. “In the future, it is hoped that the network can be built for the same patient at different time points, which will be more accurate in identifying biomarkers.”
Disclosure: The study authors reported no conflicts of interest.